International Journal of Head and Neck Surgery

Register      Login

VOLUME 9 , ISSUE 2 ( April-June, 2018 ) > List of Articles

ORIGINAL ARTICLE

What is the Current Evidence Base for Management of Oropharyngeal Cancer?

Jeffrey Lancaster, Mererid Evans, Terry M Jones

Keywords : Chemotherapy, Clinical trials, Head and neck, Oropharynx, Radiotherapy, Transoral laser surgery, Transoral robotic surgery,Cancer

Citation Information : Lancaster J, Evans M, Jones TM. What is the Current Evidence Base for Management of Oropharyngeal Cancer?. Int J Head Neck Surg 2018; 9 (2):47-53.

DOI: 10.5005/jp-journals-10001-1336

License: CC BY-NC 4.0

Published Online: 00-06-2018

Copyright Statement:  Copyright © 2018; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

This review will provide a comprehensive overview of the current management of oropharyngeal cancer. The contemporary literature, as it relates to diagnosis and management, will be summarized and the existing limitations of our knowledge will be highlighted. Research questions which need to be addressed as a matter of urgency will be listed and ongoing clinical trials designed to fill the current gaps in our knowledge will be briefly described.


PDF Share
  1. Schache AG, Powell NG, Cuschieri KS, Robinson M, Leary S, Mehanna H, et al. HPV-related oropharynx cancer in the United Kingdom: an evolution in the understanding of disease etiology. Cancer Res 2016 Nov;76(22):6598-6606.
  2. O'Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, Lee N, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol 2016 Feb;17(4):440-451.
  3. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen- Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010 Jul;363(1):24-35.
  4. Iyer NG, Dogan S, Palmer F, Rahmati R, Nixon IJ, Lee N, et al. Detailed analysis of clinicopathologic factors demonstrate distinct difference in outcome and prognostic factors between surgically treated HPV-positive and negative oropharyngeal cancer. Ann Surg Oncol 2015 Dec;22(13):4411-4421.
  5. Amin MB, Edge, SB, Greene FL, Schilsky RL, Gaspar LE, Sullivan DC, et al. AJCC cancer staging manual. 8th ed. New York: Springer International Publishing; 2017.
  6. Brierley JD, Gospodarowicz MK, Wittekind C, O'Sullivan B, Mason M, Asamura H, et al. UICC TNM classification of malignant tumours. 8th ed. Hoboken (NJ): Wiley-Blackwell; 2016.
  7. Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 2017 Mar;67(2):122-137.
  8. Schache AG, Liloglou T, Risk JM, Filia A, Jones TM, Sheard J, et al. Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res 2011 Oct;17(19):6262-6271.
  9. Junor E, Kerr G, Oniscu A, Campbell S, Kouzeli I, Gourley C, et al. Benefit of chemotherapy as part of treatment for HPV DNA-positive but p16-negative squamous cell carcinoma of the oropharynx. Br J Cancer 2012 Jan;106(2):358-365.
  10. Evans M, Newcombe R, Fiander A, Powell J, Rolles M, Thavaraj S, et al. Human Papillomavirus-associated oropharyngeal cancer: an observational study of diagnosis, prevalence and prognosis in a UK population. BMC Cancer 2013 May;13:220.
  11. Haughey BH, Hinni ML, Salassa JR, Hayden RE, Grant DG, Rich JT, et al. Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck 2011 Dec;33(12):1683-1694.
  12. Wilkie MD, Upile NS, Lau AS, Williams SP, Sheard J, Helliwell TR, et al. Transoral laser microsurgery for oropharyngeal squamous cell carcinoma: a paradigm shift in therapeutic approach. Head Neck 2016 Aug;38(8):1263-1270.
  13. Weinstein GS, Quon H, Newman HJ, Chalian JA, Malloy K, Lin A, et al. Transoral robotic surgery alone for oropharyngeal cancer: an analysis of local control. Arch Otolaryngol Head Neck Surg 2012 Jul;138(7):628-634.
  14. Haughey BH, Sinha P, Kallogjeri D, Goldberg RL, Lewis JS Jr, Piccirillo JF, et al. Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx. Oral Oncol 2016 Nov;62:11-19.
  15. Parsons JT, Mendenhall WM, Stringer SP, Amdur RJ, Hinerman RW, Villaret DB, et al. Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer 2002 Jun;94(11):2967-2980.
  16. Pignon JP, le Maitre A, Maillard E, Bourhis J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009 Jul;92(1):4-14.
  17. Health and Social Care Information Centre. National head and neck cancer audit 2014. DAHNO 10th annual report. Leeds: Health and Social Care Information Centre; 2015.
  18. Chen AY, Zhu J, Fedewa S. Temporal trends in oropharyngeal cancer treatment and survival: 1998-2009. Laryngoscope 2014 Jan;124(1):131-138.
  19. Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol 2014 Dec;32(34):3858-3866.
  20. Garden AS, Morrison WH, Wong PF, Tung SS, Rosenthal DI, Dong L, et al. Disease-control rates following intensitymodulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007 Feb;67(2):438-444.
  21. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004 Jan;22(1):69-76.
  22. Furness S, Glenny AM, Worthington HV, Pavitt S, Oliver R, et al. CSROC Expert Panel. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database Syst Rev 2010 Sep;9:CD006386.
  23. Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V, et al. Weekly low-dose versus three-weekly highdose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data. Oncologist 2017 Sep;22(9):1056-1066.
  24. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006 Feb;354(6):567-578.
  25. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014 Sep;32(27):2940-2950.
  26. Budach W, Bölke E, Kammers K, Gerber PA, Orth K, Gripp S, et al. Induction chemotherapy followed by concurrent radiochemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): a meta-analysis of randomized trials. Radiother Oncol 2016 Feb;118(2):238-243.
  27. O'Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 2013 Feb;31(5):543-550.
  28. Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Cruz Hernandez JJ, Bourredjem A, Calais G, Paccagnella A, Hitt R, et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 2013 Aug;31(23):2854-2860.
  29. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 2003 Jan;55(1):93-98.
  30. Caudell JJ, Schaner PE, Meredith RF, Locher JL, Nabell LM, Carroll WR, et al. Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009 Feb;73(2):410-415.
  31. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008 Jul;26(21):3582-3589.
  32. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 2008 Aug;26(22):3770-3776.
  33. Wilson JA, Carding PN, Patterson JM. Dysphagia after nonsurgical head and neck cancer treatment: patients’ perspectives. Otolaryngol Head Neck Surg 2011 Nov;145(5):767-771.
  34. Patterson JM, Rapley T, Carding PN, Wilson JA, McColl E. Head and neck cancer and dysphagia; caring for carers. Psychooncology 2013 Aug;22(8):1815-1820.
  35. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005 Oct;27(10):843-850.
  36. AHNS. American head and neck society 2015 annual meeting. Boston (MA): AHNS; 2015.
  37. de Almeida JR, Byrd JK, Wu R, Stucken CL, Duvvuri U, Goldstein DP, et al. A systematic review of transoral robotic surgery and radiotherapy for early oropharynx cancer: a systematic review. Laryngoscope 2014 Sep;124(9):2096-2102.
  38. Kelly K, Johnson-Obaseki S, Lumingu J, Corsten M. Oncologic, functional and surgical outcomes of primary Transoral Robotic Surgery for early squamous cell cancer of the oropharynx: a systematic review. Oral Oncol 2014 Aug;50(8): 696-703.
  39. Moore EJ, Olsen SM, Laborde RR, García JJ, Walsh FJ, Price DL, et al. Long-term functional and oncologic results of transoral robotic surgery for oropharyngeal squamous cell carcinoma. Mayo Clin Proc 2012 Mar;87(3):219-225.
  40. Genden EM, Kotz T, Tong CC, Smith C, Sikora AG, Teng MS, et al. Transoral robotic resection and reconstruction for head and neck cancer. Laryngoscope 2011 Aug;121(8):1668-1674.
  41. Quon H, Cohen MA, Montone KT, Ziober AF, Wang LP, Weinstein GS, O'Malley BW Jr. Transoral robotic surgery and adjuvant therapy for oropharyngeal carcinomas and the influence of p16 INK4a on treatment outcomes. Laryngoscope 2013 Mar;123(3):635-640.
  42. Dziegielewski PT, Teknos TN, Durmus K, Old M, Agrawal A, Kakarala K, et al. Transoral robotic surgery for oropharyngeal cancer: long-term quality of life and functional outcomes. JAMA Otolaryngol Head Neck Surg 2013 Nov;139(11):1099-1108.
  43. Leonhardt FD, Quon H, Abrahao M, O'Malley BW Jr, Weinstein GS. Transoral robotic surgery for oropharyngeal carcinoma and its impact on patient-reported quality of life and function. Head Neck 2012 Feb;34(2):146-154.
  44. Hutcheson KA, Holsinger FC, Kupferman ME, Lewin JS. Functional outcomes after TORS for oropharyngeal cancer: a systematic review. Eur Arch Otorhinolaryngol 2015 Feb;272(2): 463-471.
  45. Paleri V, Urbano TG, Mehanna H, Repanos C, Lancaster J, Roques T, et al. Management of neck metastases in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016 May;130(S2):S161-S169.
  46. Owadally W, Hurt C, Timmins H, Parsons E, Townsend S, Patterson J, et al. PATHOS: a phase II/III trial of riskstratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV) positive oropharyngeal cancer. BMC Cancer 2015 Aug;15:602.
  47. Gillison ML, Zhang Q, Jordan R, Xiao W, Westra WH, Trotti A, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 2012 Jun;30(17):2102-2111.
  48. Ferris RL, Blumenschein G, Fayette J, Guigay J, Dimitrios Colevas A, Licitra L, et al. Nivolumab for recurrent squamouscell carcinoma of the head and neck. N Engl J Med 2016 Nov;375:1856-1867.13 04 2018.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.